

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**

**阿里健康信息技術有限公司**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 00241)**

**RESULTS OF THE ANNUAL GENERAL MEETING  
HELD ON JULY 30, 2021**

The board (the “**Board**”) of directors (the “**Directors**”) of Alibaba Health Information Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, on July 30, 2021, the Company held its annual general meeting (the “**AGM**”) at which all resolutions set out in the notice of the AGM dated June 30, 2021 (the “**Notice**”) were duly passed by way of poll.

Reference is made to the circular (the “**Circular**”) of the Company dated June 30, 2021. Capitalized terms used herein shall have the same meanings as defined in the Circular unless the context requires otherwise.

## RESULTS OF THE AGM

The Board is pleased to announce that at the AGM held at Holiday Inn Express Hong Kong Causeway Bay, Meeting Room I & II, 7/F, 33 Sharp Street East, Causeway Bay, Hong Kong on Friday, July 30, 2021 at 10:30 a.m., all the ordinary resolutions set out in the Notice (the “**Resolutions**”) were duly passed by way of poll at the AGM. The poll results in respect of the Resolutions were as follows:

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
1.	To receive, consider and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the directors and auditor for the year ended March 31, 2021.	10,709,334,250 (99.98%)	2,388,000 (0.02%)
2.	To increase the authorized share capital of the Company from HK\$150,000,000, comprising of 15,000,000,000 Shares of par value HK\$0.01 each, to HK\$200,000,000, comprising of 20,000,000,000 Shares of par value HK\$0.01 each, by the creation of 5,000,000,000 Shares of par value HK\$0.01 each, each ranking <i>pari passu</i> in all respects with the existing Shares.	10,596,501,582 (98.84%)	124,084,258 (1.16%)
3.	(a) To re-elect the following retiring Directors:		
	(i) Mr. TU Yanwu as an executive Director;	10,667,302,452 (99.50%)	53,437,388 (0.50%)
	(ii) Mr. LUO Tong as an independent non-executive Director;	10,630,916,525 (99.16%)	89,823,315 (0.84%)
	(iii) Mr. WONG King On, Samuel as an independent non-executive Director; and	10,469,183,256 (97.65%)	251,556,584 (2.35%)
	(iv) Ms. HUANG Yi Fei (Vanessa) as an independent non-executive Director.	10,695,413,929 (99.76%)	25,325,911 (0.24%)
	(b) To authorize the Board to fix the Directors’ remuneration.	10,701,269,339 (99.82%)	19,470,501 (0.18%)
4.	To re-appoint Ernst & Young as the auditor of the Company and to authorize the Board to fix its remuneration.	10,628,168,181 (99.14%)	92,571,659 (0.86%)
5.	To grant a general mandate to the Directors to issue and allot Shares.	9,446,642,432 (88.12%)	1,273,943,408 (11.88%)
6.	To grant a general mandate to the Directors to repurchase Shares.	10,716,589,439 (99.96%)	4,150,401 (0.04%)

ORDINARY RESOLUTIONS		Number of Shares Voted (Approximate %)	
		For	Against
7.	To approve the addition of the aggregate amount of Shares repurchased as mentioned in ordinary resolution no. 6 to the aggregate amount that may be issued and allotted pursuant to ordinary resolution no. 5.	9,533,807,155 (88.93%)	1,186,932,685 (11.07%)
8.	To approve the grant of a mandate authorizing the Directors to grant awards of options and/or RSUs pursuant to the Share Award Scheme in respect of a maximum number of the underlying new Shares that is equivalent to 3% of the Shares in issue as at the date of passing of this resolution during the period from the date of passing this resolution until the earlier of (a) the conclusion of the Company's next annual general meeting, (b) the end of the period within which the Company is required by any applicable law or its bye-laws to hold its next annual general meeting, and (c) the date on which this resolution is varied or revoked by an ordinary resolution of the Shareholders in general meeting (the " <b>Applicable Period</b> "), and to allot, issue and deal with Shares underlying the options and/or RSUs granted pursuant to the Share Award Scheme during the Applicable Period as and when such options and/or RSUs vest.	9,895,568,552 (92.30%)	825,017,288 (7.70%)

*Notes:*

- (1) The full text of the Resolutions is set out in the Notice.
- (2) As at the date of the AGM:
  - (a) the total number of Shares in issue was 13,489,209,542. Since the last monthly return submitted by the Company under Rule 13.25B of the Listing Rules on July 8, 2021, the Company had issued a total of 844,500 Shares due to the exercise of share options by certain employees under the Company's share award scheme. Such share options were not exercised by a Director and hence a next day disclosure return was not submitted by the Company under Rule 13.25A(1) of the Listing Rules;
  - (b) each of the CP Trustee and the NCP Trustee held 2,750,550 and 5,411,039 Shares, respectively, representing approximately 0.020% and 0.040% of the issued share capital of the Company, respectively. Each of the CP Trustee and the NCP Trustee is not entitled to exercise any voting rights and is required to abstain from voting on Resolution no. 8 in relation to the 2021 Share Award Mandate. The CP Trustee and the NCP Trustee had abstained from voting on Resolution no. 8;

- (c) the total number of Shares entitling the Shareholders to attend and vote for or against the Resolutions (other than Resolution no. 8) at the AGM was 13,489,209,542 and the total number of Shares entitling the Shareholders to attend and vote for or against Resolution no. 8 was 13,481,047,953;
  - (d) the total number of Shares entitling the Shareholders to attend and vote only against the Resolutions at the AGM was nil; and
  - (e) save as disclosed, there were no Shares entitling the holder to attend and abstain from voting in favour of the Resolutions at the AGM as set out in Rule 13.40 of the Listing Rules, no Shareholders were required under the Listing Rules to abstain from voting on the Resolutions, and there were no Shareholders that had stated their intention in the Circular to vote against or abstain from voting in respect of any Resolutions proposed at the AGM.
- (3) Tricor Secretaries Limited, the Company's branch share registrar and transfer office in Hong Kong, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

As more than 50% of the total votes were cast in favour of each of Resolutions no. 1 to no. 8, all Resolutions were duly passed as ordinary resolutions of the Company.

By Order of the Board  
**ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED**  
**ZHU Shunyan**  
*Chairman and Chief Executive Officer*

Hong Kong, July 30, 2021

*As at the date of this announcement, the Board comprises seven Directors, of whom (i) two are executive Directors, namely Mr. ZHU Shunyan and Mr. TU Yanwu; (ii) two are non-executive Directors, namely Mr. WU Yongming and Mr. XU Hong; and (iii) three are independent non-executive Directors, namely Mr. LUO Tong, Mr. WONG King On, Samuel and Ms. HUANG Yi Fei (Vanessa).*